# US 8,278,329 B2 · Diarylalkene derivatives and novel diarylalkane derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,329 B2
- Document ID: US8278329B2
- Status: Granted
- Kind: B2
- Application number: 11/924,997
- Filed: 2007-10-26
- Published: 2008-03-06
- Granted: 2012-10-02
- Earliest claimed: 2001-08-31
- Assignees: Ajinomoto Co., Inc.
- Inventors: Takashi Yamamoto; Seiji Niwa; Kayo Otani; Seiji Ohno; Hajime Koganei; Satoshi Iwayama; Akira Takahara; Yukitsugu Ono; Tomoko Takeda; Shinichi Fujita; Keiko Moki
- Web page: https://patentgrep.com/patent/US8278329B2

## CPC

- C07D 295/205: Radicals derived from carbonic acid
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/36: Opioid-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 237/06: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 271/20: to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07C 271/22: to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07D 211/70: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The invention relates to a compound represented by the following general formula (1) or its analogue, which selectively inhibit N-type calcium channels or its analogue, and to a method for treating pain etc. comprising the compound represented by the following general formula (1) or its analogue to a patient in need of such treatment: wherein, A represents CH═CH, etc., a, b, c and d represents CH etc., R1, R2, R3, R4, R5 and R6 represents H etc., V—W represents C═C, etc., n represents 0 to 3, Y1 represents O etc., B represents —(CH2)vCHR21 wherein v is 0 to 3, R21 represents H, a lower alkyl group or the like, etc., G represents —CO—, a covalent bond, etc., m is 0 to 6, R7 and R8 represents H, a lower alkyl group, —COR18a, —COOR20 wherein R18a and R20 each represents a lower alkyl group or the like, etc.

## Claims

### Claim 1

A compound of formula (1), or a pharmaceutically acceptable salt thereof:
wherein A represents —CH═CH—;
a, b, c and d are each selected from the group consisting of CR1 and CR2;
R1, R2 and R4 each independently represent H, a halogen, —CF3, —OR14, —COR14, —SR14, —S(O)tR15, —N(R14)2, —NO2, —OC(O)R14, —CO2R14, —OCO2R14, —CN, —NR14COOR15, —SR15C(O)OR15 or —SR15N(R16)2 wherein R14 represents H, a lower alkyl, an aryl or an aryl-lower alkyl group, R15 represents a lower alkyl or an aryl group, R16 is independently selected from the group consisting of H and —C(O)OR15, and t represents 1 or 2;
R3 represents H;
V—W represents C═C;
n represents 2 or 3;
R5 and R6 each independently represent H, a halogen, —CF3, a lower alkyl or an aryl;
or R5 and R6 together form ═O or ═S;
Y1 represents O or S;
B represents NR17a, —NR17a(CH2)vCHR21—, —(CH2)vCHR21— wherein v represents 0 to 3, R17a represents H, a lower alkyl or an aryl, R21 represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, —CH2SH, —CH2CH2SCH3, —CH2(CO)NH2, —CH2CH2(CO)NH2, —(CH2)w—COOR29, —(CH2)w—NR29R30 wherein R29 and R30 each independently represent hydrogen atom or a lower alkyl group, and w represents 0 to 4, —(CH2)3NHC(NH2)═NH, benzyl, 4-hydroxybenzyl, 3-indoylmethyl or 5-imidazoylmethyl;
G represents —(CO)—, —(SO)—, —(SO2)—or a covalent bond;
m represents 0 to 6;
R7 and R8 each independently represent H, a lower alkyl, an aryl, —(CO)R18a, —(CS)R18a, —(CO)NR18aR19a, —(CS)NR18aR19a wherein R18a represents H, a lower alkyl, an aryl or a cycloalkyl group which may have a hetero atom in the ring, R19a represents H, a lower alkyl or an aryl; or R18a and R19a together form a cycloalkyl which may have a halogen, —CF3, a lower alkyl or an aryl as a substituent, —(CO)OR20 or —(CS)OR20 wherein R20 represents an alkyl group having 1 to 12 carbon atoms, an aryl group or a cycloalkyl group which may have a hetero atom in the ring, or a group of formula (5):
wherein Y4 and Y3 each represent O or S; s represents 0 to 6;
E represents NR22 or CHR23 wherein R22 represents H, a lower alkyl or aryl; and R23 represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, —CH2SH, —CH2CH2SCH3, —CH2(CO)NH2, —CH2CH2(CO)NH2, —CH2COOH, —CH2CH2COOH, —(CH2)4NH2, —(CH2)3NHC(NH2)═NH, benzyl, 4-hydroxybenzyl, 3-indoylmethyl or 5-imidazoylmethyl;
R24 represents H, a lower alkyl or an aryl;
R25 represents H, a lower alkyl, an aryl, —OR18a, —(CO)R18a, —(CS)R18a, —(CO)NR18aR19a, —(CS)NR18aR19a, —(CO)OR20 or —(CS)OR20 wherein R18a, R19a and R20 are as defined above.

### Claim 2 (depends on 1)

The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein in formula (1)
B represents NR17a, CHR21 and CH2CHR21 wherein R17a represents H, a lower alkyl or an aryl, R21 represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, —CH2SH, —CH2CH2SCH3, —CH2(CO)NH2, —CH2CH2(CO)NH2, —CH2COOH, —CH2CH2COOH, —(CH2)4NH2, —(CH2)3NHC(NH2)═NH, benzyl, 4-—hydroxybenzyl, 3-indoylmethyl or 5-imidazoylmethyl; and
R18a represents H, a lower alkyl or an aryl, and R19a represents H, a lower alkyl or aryl;
or R18a and R19a together form a cycloalkyl group which may have a halogen, —CF3, a lower alkyl or an aryl as a substituent, and R25 and R27 each represent H, a lower alkyl, an aryl, —(CO)R18a, —(CS)R18a, —(CO)NR18aR19a, —(CS)NR18aR19a, —(CO)OR20 or —(CS)OR20 .

### Claim 3 (depends on 2)

The compound or a pharmaceutically acceptable salt thereof according to claim 2, wherein in formula (1)
a, b, c and d each represent CH;
R3 and R4 each represent hydrogen atom;
R5 and R6 each represent hydrogen atom;
or R5 and R6 together form ═O;
n represents 1 or 2;
Y1 represents O;
B represents NR17a, CHR21— or, CH2CHR21 wherein R21 represents H, a lower alkyl, an aryl or —CH2OH;
G represents —(CO)—or a covalent bond;
m represents 0 to 6;
R7 and R8 each independently represent H, a lower alkyl, an aryl, —(CO)R18a wherein R18a represents H, a lower alkyl or an aryl, —(CO)NR18aR19a wherein R19a represents H, a lower alkyl or an aryl; or R18a and R19a together form a cycloalkyl which may have a halogen, —CF3, a lower alkyl or an aryl as a substituent, —(CO)OR20 wherein R20 represents an alkyl group having 1 to 12 carbon atoms, an aryl group or a cycloalkyl group which may contain a hetero atom in the ring, or a group of formula (8):
wherein Y4 and Y3 each represent O;
s represents 1 or 2;
E represents CHR23 wherein R23 represents H,
R24 represents H;
R25 represents —(CO)OR20.

### Claim 4 (depends on 3)

The compound or a pharmaceutically acceptable salt thereof according to claim 3, wherein in formula (1)
a, b, c and d each represent CH;
R1 and R2 each represent H;
R3 and R4 each represent H;
n represents 2;
R5 and R6 each represent H; and
Y1 represents O.

### Claim 5 (depends on 1)

The compound or a pharmaceutically acceptable salt according to claim 1, wherein in formula (1)
B represents —(CH2)v—CHR21 wherein v represents 2 or 3, R21 represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, —CH2SH, —CH2CH2SCH3, —CH2(CO)NH2, —CH2CH2(CO)NH2, benzyl, 4-hydroxybenzyl, 3-indoylmethyl or 5-imidazoylmethyl; and
R18a represents H, a lower alkyl or an aryl, and R19a represents H, a lower alkyl or aryl; or R18a and R19a together form a cycloalkyl group which may have a halogen, —CF3, a lower alkyl or an aryl as a substituent.

### Claim 6 (depends on 5)

The compound or a pharmaceutically acceptable salt thereof according to claim 5, wherein in formula (1),
a, b, c and d each represent CH;
R1, R2, R3, R4, R5 and R6 each represent H;
m represents 0 and n represents 2;
Y1 represents O, G represents a covalent bond, and
R7 and R8 each independently represent H, a lower alkyl, —(CO)R18a wherein R18a represents H, a lower alkyl or an aryl, —(CO)OR20 wherein R20 represents an alkyl group having 1 to 12 carbon atoms or an aryl.

### Claim 7

A compound represented by formula (11), or a pharmaceutically acceptable salt thereof:
wherein R28 represents an alkyl group having 1 to 12 carbon atoms, a cycloalkyl group having 3 to 12 carbon atoms or a cycloalkyl group which may have a hetero atom in the ring.

### Claim 8

A compound of formula (1-A), or a pharmaceutically acceptable salt thereof:
wherein A represents —CH═CH—;
B represents —(CH2)v—CHR21 wherein v represents 0 to 3, R21 represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, —(CH2)w—COOR29 or —(CH2)w—NR29R30 wherein R29 and R30 each independently represent hydrogen atom or a lower alkyl group and w represents 0 to 4;
G represents —(CO)— or a covalent bond;
m represents 0 to 6; and
R7 and R8 each independently represent H, a lower alkyl, an aryl, —(CO)R18a wherein R18a represents H, a lower alkyl, an aryl or a cycloalkyl group which may contain a hetero atom in the ring, or —(CO)OR20 wherein R20 represents an alkyl group having 1 to 12 carbon atoms, an aryl or a cycloalkyl group which may have a hetero atom in the ring.

### Claim 9

A compound of the following formulae, or a pharmaceutically acceptable salt thereof:

### Claim 10

A compound of the following formulae, or a pharmaceutically acceptable salt thereof:

### Claim 11 (depends on 1)

A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt thereof according to claim 1 and at least one pharmaceutically acceptable adjuvant.

### Claim 12 (depends on 2)

A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt thereof according to claim 2 and at least one pharmaceutically acceptable adjuvant.

### Claim 13 (depends on 5)

A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt thereof according to claim 5 and at least one pharmaceutically acceptable adjuvant.

### Claim 14 (depends on 7)

A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt thereof according to claim 7 and at least one pharmaceutically acceptable adjuvant.

### Claim 15 (depends on 8)

A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt thereof according to claim 8 and at least one pharmaceutically acceptable adjuvant.

### Claim 16 (depends on 9)

A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt thereof according to claim 9 and at least one pharmaceutically acceptable adjuvant.

### Claim 17 (depends on 10)

A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt thereof according to claim 10 and at least one pharmaceutically acceptable adjuvant.

### Claim 18 (depends on 9)

The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said compound is:

### Claim 19 (depends on 9)

The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said compound is:

### Claim 20 (depends on 9)

The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said compound is:

### Claim 21 (depends on 10)

The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein said compound is:

### Claim 22 (depends on 10)

The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein said compound is:

### Claim 23 (depends on 10)

The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein said compound is:
